Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.

	Q1 2024	Q1 2023	% change
	€m	€m	Actual	CER1
Growth platforms2	509.7	452.0	12.8%	16.2%
New medicines3	45.5	14.3	n/a	n/a
Somatuline	257.8	263.2	-2.0%	-1.3%
Other	9.5	12.4	-23.8%	-20.5%
Total Sales	822.4	741.9	10.9%	13.3%

Highlights

• Total-sales growth of 13.3% at CER¹, or 10.9% as reported, driven by the 16.2%¹ increase in sales of the growth platforms² and the increased contributions from new medicines, while Somatuline sales declined by only 1.3%¹

• Regulatory approval and launch of Onivyde in the U.S. as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC)
• Confirmation of financial guidance for 2024

“An excellent first-quarter performance has laid a solid foundation for Ipsen's growth in 2024”, commented David Loew, Chief Executive Officer, Ipsen. “The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines. Moreover, the pipeline continues to deliver, illustrated this quarter by the regulatory approval in the U.S. of Onivyde as a first-line treatment for pancreatic cancer.

“This year marks a pivotal period for our growth plans, with the launches of four new medicines or indications. Our focus remains on the performance of our portfolio and the expansion of our pipeline, and a well-defined strategy for sustainable growth centred on enhancing the lives and medical outcomes of patients.”

Full-year 2024 guidance

Ipsen has confirmed its financial guidance for 2024, which excludes the impact of any potential additional late-stage⁴ external-innovation opportunities: